PolarityTE (NSDQ:PTE) said it has begun enrolling patients in two new randomized clinical trials of its SkinTE regenerative tissue product for chronic wounds.
The trials will evaluate the SkinTE’s effectiveness in treating diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). SkinTE is a human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement. The Salt Lake City, Utah-based company has said the product produces full-thickness skin that has sweat glands and can grow hair. SkinTE has launched regionally.
Get the full story on our sister site, Drug Delivery Business.